Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:IBIO

iBio Q2 2026 Earnings Report

iBio logo
$1.61 +0.03 (+1.90%)
Closing price 05/5/2026 04:00 PM Eastern
Extended Trading
$1.61 0.00 (0.00%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

iBio EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q2 2026
Date
2/10/2026
Time
After Market Closes
Conference Call Date
Tuesday, February 10, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

iBio's Q3 2026 earnings is estimated for Friday, May 8, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, May 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

iBio's Q2 2026 Press ReleasePress Release
(8-K)
iBio's Q2 2026 Quarterly reportQuarterly report
(10-Q)

iBio Earnings Headlines

iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600
April 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/ibio-ibio-receives-regulatory-clearance-191446078.html
iBio, Inc. Common Stock (IBIO)
April 11, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/ibio/pre-market?page=1
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 6 at 1:00 AM  |  Brownstone Research (Ad)
Ibio (IBIO) Receives a Buy from Chardan Capital
April 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IBIO/pressreleases/1233851/ibio-ibio-receives-a-buy-from-chardan-capital/
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia
April 8, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/ibio-stock-is-soaring-today-after-ibio-s-muscle-preserving-drug-receives-approval-for-human-trial-in-australia/ar-AA20pNVX
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
April 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/08/3269981/0/en/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australia.html
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

View iBio Profile
Earnings Tools